William D. Shrader Email & Phone Number

Experienced leader of R&D teams in neurodegeneration, inflammation, cardiovascular disease and oncology, resulting in 4 drugs advancing through phase 2 clinical trials in ALS, Parkinson’s disease, Pancreatic cancer, Rett syndrome, Friedreich’s ataxia and Leigh syndrome.Seasoned executive in creating productive co-development drug partnerships and business development in/out-licensing activities.Highlights:• Invented and developed EPI-589 for adult neurodegenerative diseases, currently in phase II clinical studies for amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Licensed to Sumitomo in one of the 10 largest deals of that year.• Discovered and developed the 15-lipoxygenase inhibitor, EPI-743, which was recently sold to PTC Therapeutics. Currently in Phase II for pediatric orphan mitochondrial disease (Friedreich’s Ataxia, Leigh Syndrome) and Parkinson’s disease.• Invented and developed the factor VIIa/Tissue Factor inhibitor PCI-27483. Licensed to AbbVie and is currently in phase II for Pancreatic cancer.A medicinal chemist with an extensive track record in integrating multiple disciplines (medicinal chemistry, enzymology, ADME, PK/PD, in-vitro and in-vivo pharmacology, biology, toxicology, process chemistry, clinical biomarkers/translation, regulatory and intellectual property) to rapidly advance drug discovery and development programs into clinical trials.Innovator of translational biomarkers of neuroinflammation, in ALS and PD clinical trials to demonstrate drug/target engagement.Author of 30 peer-reviewed scientific publications and inventor of 21 issued US patents.

Listed skills include Chemistry, Life Sciences, Pharmaceuticals, Drug Discovery, and 28 others.